OA11231A - Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer - Google Patents

Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer Download PDF

Info

Publication number: OA11231A
Authority: OA; OAPI
Prior art keywords: alkyl; phenyl; halo; amino; hydroxy
Prior art date: 1997-06-16

Application number

OA9900276A

Other languages

English (en)

Inventor

Shama Mohammed Kajiiji

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-16

Filing date

1999-12-10

Publication date

2003-05-26

1999-12-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-05-26 Publication of OA11231A publication Critical patent/OA11231A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA9900276A 1997-06-16 1999-12-10 Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer OA11231A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4963897P	1997-06-16	1997-06-16

Publications (1)

Publication Number	Publication Date
OA11231A true OA11231A (en)	2003-05-26

Family

ID=21960890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900276A OA11231A (en)	1997-06-16	1999-12-10	Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer

Country Status (37)

Country	Link
EP (1)	EP0986387B1 (xx)
JP (1)	JP3713051B2 (xx)
KR (1)	KR100392573B1 (xx)
CN (1)	CN1259868A (xx)
AP (1)	AP9801261A0 (xx)
AR (1)	AR013090A1 (xx)
AT (1)	ATE235905T1 (xx)
BG (1)	BG103946A (xx)
BR (1)	BR9810616A (xx)
CA (1)	CA2294399C (xx)
CO (1)	CO4950607A1 (xx)
DE (1)	DE69812933T2 (xx)
DK (1)	DK0986387T3 (xx)
DZ (1)	DZ2518A1 (xx)
EA (1)	EA199901043A1 (xx)
ES (1)	ES2196559T3 (xx)
GT (1)	GT199800081A (xx)
HN (1)	HN1998000091A (xx)
HR (1)	HRP980328B1 (xx)
HU (1)	HUP0004624A3 (xx)
ID (1)	ID23014A (xx)
IL (1)	IL132765A0 (xx)
IS (1)	IS5259A (xx)
MA (1)	MA24569A1 (xx)
NO (1)	NO996206L (xx)
NZ (1)	NZ500662A (xx)
OA (1)	OA11231A (xx)
PA (1)	PA8453601A1 (xx)
PE (1)	PE82899A1 (xx)
PL (1)	PL337651A1 (xx)
PT (1)	PT986387E (xx)
SK (1)	SK169699A3 (xx)
TN (1)	TNSN98088A1 (xx)
TR (1)	TR199903074T2 (xx)
UA (1)	UA57081C2 (xx)
WO (1)	WO1998057633A1 (xx)
ZA (1)	ZA985182B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999058505A2 (en) *	1998-05-12	1999-11-18	Warner-Lambert Company	Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
WO2000016778A1 (en) *	1998-09-24	2000-03-30	Merck & Co., Inc.	A method of treating cancer
EP1006113A1 (en)	1998-12-02	2000-06-07	Pfizer Products Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) *	1999-05-07	2000-11-21	Brigham And Women's Hospital	Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en)	2000-11-06	2004-03-23	Bristol-Myers Squibb Pharma Company	Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1395577A1 (en)	2000-12-19	2004-03-10	Pfizer Products Inc.	Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60122939T2 (de)	2000-12-21	2007-01-11	Nitromed, Inc., Bedford	Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en)	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) *	2004-01-16	2008-06-11	Nat Health Research Institutes	Cancer therapy
US8168667B2 (en)	2006-05-31	2012-05-01	Galapagos Nv	Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en)	2008-09-11	2018-09-26	Galapagos Nv	Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0856315B1 (en) *	1995-08-09	2005-08-24	Banyu Pharmaceutical Co., Ltd.	Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

1998
- 1998-05-06 UA UA99126842A patent/UA57081C2/uk unknown
- 1998-06-05 NZ NZ500662A patent/NZ500662A/en unknown
- 1998-06-05 PT PT98921688T patent/PT986387E/pt unknown
- 1998-06-05 TR TR1999/03074T patent/TR199903074T2/xx unknown
- 1998-06-05 EP EP98921688A patent/EP0986387B1/en not_active Expired - Lifetime
- 1998-06-05 KR KR10-1999-7011860A patent/KR100392573B1/ko not_active IP Right Cessation
- 1998-06-05 HU HU0004624A patent/HUP0004624A3/hu unknown
- 1998-06-05 CN CN98805968A patent/CN1259868A/zh active Pending
- 1998-06-05 JP JP50403099A patent/JP3713051B2/ja not_active Expired - Fee Related
- 1998-06-05 BR BR9810616-3A patent/BR9810616A/pt not_active Application Discontinuation
- 1998-06-05 WO PCT/IB1998/000881 patent/WO1998057633A1/en not_active Application Discontinuation
- 1998-06-05 EA EA199901043A patent/EA199901043A1/ru unknown
- 1998-06-05 CA CA002294399A patent/CA2294399C/en not_active Expired - Fee Related
- 1998-06-05 IL IL13276598A patent/IL132765A0/xx unknown
- 1998-06-05 SK SK1696-99A patent/SK169699A3/sk unknown
- 1998-06-05 DK DK98921688T patent/DK0986387T3/da active
- 1998-06-05 AT AT98921688T patent/ATE235905T1/de not_active IP Right Cessation
- 1998-06-05 ES ES98921688T patent/ES2196559T3/es not_active Expired - Lifetime
- 1998-06-05 DE DE69812933T patent/DE69812933T2/de not_active Expired - Fee Related
- 1998-06-05 ID IDW991597A patent/ID23014A/id unknown
- 1998-06-05 PL PL98337651A patent/PL337651A1/xx unknown
- 1998-06-09 HN HN1998000091A patent/HN1998000091A/es unknown
- 1998-06-11 AP APAP/P/1998/001261A patent/AP9801261A0/en unknown
- 1998-06-12 PE PE1998000500A patent/PE82899A1/es not_active Application Discontinuation
- 1998-06-12 AR ARP980102812A patent/AR013090A1/es unknown
- 1998-06-15 GT GT199800081A patent/GT199800081A/es unknown
- 1998-06-15 TN TNTNSN98088A patent/TNSN98088A1/fr unknown
- 1998-06-15 DZ DZ980128A patent/DZ2518A1/xx active
- 1998-06-15 PA PA19988453601A patent/PA8453601A1/es unknown
- 1998-06-15 MA MA25114A patent/MA24569A1/fr unknown
- 1998-06-15 ZA ZA9805182A patent/ZA985182B/xx unknown
- 1998-06-16 HR HR980328A patent/HRP980328B1/xx not_active IP Right Cessation
- 1998-06-16 CO CO98034148A patent/CO4950607A1/es unknown
1999
- 1999-11-19 IS IS5259A patent/IS5259A/is unknown
- 1999-12-03 BG BG103946A patent/BG103946A/bg unknown
- 1999-12-10 OA OA9900276A patent/OA11231A/en unknown
- 1999-12-15 NO NO996206A patent/NO996206L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100392573B1 (ko)	2003-07-23
ES2196559T3 (es)	2003-12-16
AP9801261A0 (en)	1999-12-11
JP3713051B2 (ja)	2005-11-02
IS5259A (is)	1999-11-19
SK169699A3 (en)	2000-06-12
PT986387E (pt)	2003-06-30
CA2294399A1 (en)	1998-12-23
EP0986387A1 (en)	2000-03-22
NO996206D0 (no)	1999-12-15
MA24569A1 (fr)	1998-12-31
DZ2518A1 (fr)	2003-02-01
NZ500662A (en)	2001-10-26
DK0986387T3 (da)	2003-07-14
JP2000513031A (ja)	2000-10-03
EA199901043A1 (ru)	2000-06-26
CA2294399C (en)	2004-03-16
DE69812933T2 (de)	2003-11-06
ZA985182B (en)	1999-12-17
NO996206L (no)	2000-02-15
PA8453601A1 (es)	2000-05-24
AR013090A1 (es)	2000-12-13
ID23014A (id)	1999-12-30
PL337651A1 (en)	2000-08-28
HRP980328A2 (en)	1999-04-30
BG103946A (bg)	2000-07-31
GT199800081A (es)	1999-12-07
PE82899A1 (es)	1999-08-26
UA57081C2 (uk)	2003-06-16
HN1998000091A (es)	1999-09-29
IL132765A0 (en)	2001-03-19
AU7445998A (en)	1999-01-04
KR20010013839A (ko)	2001-02-26
WO1998057633A1 (en)	1998-12-23
HRP980328B1 (en)	2002-06-30
AU724676B2 (en)	2000-09-28
BR9810616A (pt)	2000-09-12
ATE235905T1 (de)	2003-04-15
HUP0004624A3 (en)	2002-11-28
HUP0004624A2 (hu)	2001-10-28
EP0986387B1 (en)	2003-04-02
TNSN98088A1 (fr)	2005-03-15
DE69812933D1 (de)	2003-05-08
CO4950607A1 (es)	2000-09-01
CN1259868A (zh)	2000-07-12
TR199903074T2 (xx)	2000-05-22

Publication	Publication Date	Title
US7307071B2 (en)	2007-12-11	RAF-MEK-ERK pathway inhibitors to treat cancer
US20050014783A1 (en)	2005-01-20	Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
OA11231A (en)	2003-05-26	Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer
KR101354237B1 (ko)	2014-01-22	골수종 치료를 위한 ｈｄａｃ 저해제의 용도
TWI786723B (zh)	2022-12-11	噠嗪并吲哚衍生物及其用途
EP2182941B1 (en)	2018-02-28	Multikinase inhibitors for use in the treatment of cancer
US20190358229A1 (en)	2019-11-28	Pac-1 combination therapy
JP2007063288A (ja)	2007-03-15	エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
Tamanoi et al.	2013	Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions
Chin et al.	1999	Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB
US20190151289A1 (en)	2019-05-23	Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) Histone Demethylase
AU724676C (en)	2001-05-03	Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
KR19990082064A (ko)	1999-11-15	피페라진 옥시란 유도체를 사용하여 신생 세포의 사멸을유도하는 방법
US20030114503A1 (en)	2003-06-19	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
EP1684747B1 (en)	2008-07-09	Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
MXPA99011798A (en)	2000-06-01	FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
US20020151563A1 (en)	2002-10-17	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
CZ448699A3 (cs)	2000-04-12	Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
WO2018039467A1 (en)	2018-03-01	Inhibitors of-bcr-abl mutants and use thereof
WO2005105078A1 (en)	2005-11-10	Indole derivatives useful for treating resistance to antitumour agents
WO2021086912A1 (en)	2021-05-06	Combined pikfyve and p38 map kinase inhibition for treating cancer
WO2002002116A2 (en)	2002-01-10	Therapeutic treatment of cancer with a protein kinase c inhibitor
CA2120234A1 (en)	1993-04-29	2-aminopropan-1,3-diol chemotherapeutic agents
Halabi	2012	A Synthetic Lethal Screen for NF-kB-Dependent Plasma Cell Disorders
Dai et al.	0	Vorinostat synergistically potentiates MK-0457 lethality in chronic